Acasti is a biopharmaceutical company focused on the research, development, and commercialization of prescription drugs using omega-3 fatty acids derived from krill oil. Its lead product candidate is CaPre, an omega-3 phospholipid therapeutic to treat patients with hypertriglyceridemia.